Alliance for Neuroimaging Research

(Chicago, IL, USA).

The research will use Miicro's preclinical drug discovery platform that integrates neuroimaging technology with other measure to provide a picture of brain activity. Dr. Patricia Goldman-Rakic, known for her work in cognition, will lead Yale's contribution to the research. The cause of schizophrenia and the reason that certain drugs are more effective than others remain unknown, creating the need for new insights and advances in pharmaceuticals.

Specifically, researchers will use Miicro's OMEI (optimized metabolic effects identification) neuroimaging method, which combines positron emission tomography (PET) with data collection and analysis techniques to measure the subtle effects of drugs on the brain. Miicro focuses on the development and discovery of improved central nervous system therapeutics using a novel integrated neurotechnology platform.

"We are very excited about the opportunity to formalize a collaborative relationship with Dr. Goldman-Rakic and Yale to learn more about the basis of schizophrenia,” said John Metz, Ph.D., chief scientist of Miicro.





Related Links:
Yale
Miicro